| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11633478 | AZURITY | Compositions and kits for Omeprazole suspension |
Jul, 2039
(15 years from now) | |
| US11103492 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(15 years from now) | |
| US10751333 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(15 years from now) | |
Konvomep is owned by Azurity.
Konvomep contains Omeprazole; Sodium Bicarbonate.
Konvomep has a total of 3 drug patents out of which 0 drug patents have expired.
Konvomep was authorised for market use on 30 August, 2022.
Konvomep is available in for suspension;oral dosage forms.
The generics of Konvomep are possible to be released after 16 July, 2039.
Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient
Market Authorisation Date: 30 August, 2022
Treatment: NA
Dosage: FOR SUSPENSION;ORAL
More Information on Dosage
KONVOMEP family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic